Akira Setoguchi
Papers
1
Total Citations
7
H-Index
1
About
Akira Setoguchi is a leading radiation oncologist whose work centers on advancing stereotactic ablative body radiotherapy (SABR) for metastatic lung tumors, with a particular focus on the CyberKnife system. His major contribution lies in demonstrating the feasibility and safety of delivering a central high dose using this robotic, real-time image-guided platform, which achieves steep dose gradients through multidirectional irradiation. This approach allows for precise dose escalation to the gross tumor volume while sparing surrounding healthy tissue—a critical challenge in treating central lung lesions. Setoguchi’s research has garnered significant attention, with his most-cited paper accumulating 7 citations since 2023, reflecting its immediate impact on clinical practice. His work is notable for bridging technological innovation with practical treatment protocols, offering a potential paradigm shift for patients with oligometastatic disease who are not candidates for surgery. By refining SABR techniques, Setoguchi has contributed to expanding the therapeutic arsenal against metastatic lung cancer, improving both local control and patient quality of life. His ongoing investigations continue to shape the future of non-invasive, high-precision radiotherapy.
Research Focus
Key Achievements
Top Papers
- 1